Indolepropionamide (IPAM) — Safety, Research, Risks & Legal Status

Not medical advice. Indolepropionamide (IPAM) is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	IPAM; Indole-3-propionamide; IPA (ambiguous - also used for indole-3-propionic acid); 3-(indol-3-yl)propanamide; CAS 5814-93-7
Category	Research Chemical
Molecular formula	C₁₁H₁₂N₂O; CAS 5814-93-7; FDA UNII 6RD94WRM73
Drug class	Small-molecule indole derivative; endogenous compound; proposed mitochondrial Complex I stabilizer
Development stage	Preclinical only - no human trials; patent applications abandoned; no active pharmaceutical pipeline identified
Most striking preclinical finding	~300% lifespan extension in rotifers (Philodina roseola) at 10-30 µM - animal model only, not translatable to humans
Structural note	Described as a 'reversed melatonin' structural motif; distinct from indole-3-propionic acid (IPA) despite abbreviation overlap
Origin	NIH-supported academic research (grant AG16783); no current commercial developer advancing to clinical trials
US legal status	Not FDA-approved as a drug or dietary supplement. Holds an FDA UNII identifier (6RD94WRM73) but no regulatory review has been completed. Sold commercially by chemical suppliers (EON Biotech, Chem-Impex, Crescent Chemical) as a research compound only. Not legal for human consumption in the United States. Patent applications (US20070105937A1; WO2005062851A2) were filed with NIH support but the US application was abandoned and never issued; patent protection has lapsed.

What is Indolepropionamide (IPAM)?

Indolepropionamide (IPAM) is a small-molecule indole derivative with a structural motif sometimes described as analogous to melatonin. It is an endogenous compound - detectable in mammalian tissue - and is under preclinical investigation primarily as a mitochondria-targeted agent. Its proposed mechanism centers on stabilizing Complex I of the mitochondrial electron transport chain, reducing reactive oxygen species (ROS) production through decreased electron leakage rather than direct free-radical scavenging. All evidence for its effects is currently preclinical; no human trials have been conducted under this compound's name.

How it works

IPAM is reported to bind Complex I of the mitochondrial respiratory chain, reducing electron leakage and thereby lowering ROS output. In aged rodent brain mitochondria, nanomolar concentrations restored age-dependent declines in mitochondrial membrane potential and enhanced Complex I and Complex IV enzymatic activities. This distinguishes it mechanistically from classical antioxidants, which neutralize ROS after generation rather than suppressing their source. In neuronal cell culture, IPAM has also been shown to inhibit amyloid-beta aggregation and associated cytotoxicity, though the mechanism for this effect is not fully characterized. All mechanistic data derive from animal or in vitro models.

Background & history

Research on IPAM appears to have originated in academic and NIH-supported settings in the early-to-mid 2000s, with patent applications filed in late 2004 (WO2005062851A2; US20070105937A1). A notable PLOS ONE study published in 2010 (PMID 20421998) reported extraordinary lifespan extension in the rotifer Philodina roseola and mitochondrial protection in rodent models. Despite NIH grant support (AG16783) and the initial patent filings, the US patent application was abandoned and no commercial developer has advanced IPAM into clinical-stage development. The compound has remained a research-phase molecule with no identified active pharmaceutical or biotech pipeline as of the knowledge cutoff.

What the research says

All published data are preclinical. In rotifers (Philodina roseola), IPAM at 10-30 µM concentrations produced lifespan extension reported as the largest ever observed in that species (~300%), along with improved offspring production. In rodent brain mitochondria, nanomolar concentrations reversed age-associated declines in mitochondrial function and protected against mitochondrial toxins in both young and aged animals. In Drosophila melanogaster, IPAM modulated lifespan, and aged mouse models showed improved muscle function and reduced bone loss. In neuronal cell culture, IPAM inhibited amyloid-beta aggregation and cytotoxicity. There are no published human clinical trials for IPAM specifically. Data on the structurally related but distinct compound indole-3-propionic acid (IPA) show limited human tolerability evidence (single doses up to 1200 mg in Friedreich's ataxia trials with no serious adverse events reported), but this cannot be extrapolated to IPAM.

Reported effects

Preclinical: Mitochondrial membrane potential stabilization in aged rodent brain tissue at nanomolar concentrations
Preclinical: Reduction of ROS production via Complex I electron leakage suppression
Preclinical: Restoration of Complex I and IV enzymatic activity in aged tissue
Preclinical: Lifespan extension in rotifer model organism (~300% at 10-30 µM; animal model only, not translatable to humans)
Preclinical: Inhibition of amyloid-beta aggregation and cytotoxicity in neuronal cell culture
Preclinical: Improved muscle function and reduced bone loss in aged mice
No human efficacy data exist for any of the above effects

Dosing & administration (informational)

The published preclinical literature used concentrations of 10-30 µM in rotifer assays and nanomolar concentrations in rodent brain mitochondrial preparations. These are experimental in vitro and animal-model figures presented here for informational reference only. No human dosing has been studied, no safe or effective human dose has been established, and no dosing guidance can be derived from animal data alone. Consult a licensed clinician before considering any investigational compound.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

No human safety data exist; all tolerability observations are from animal or in vitro models
No toxicity reported in preclinical models at studied concentrations
Favorable in vitro safety profile at physiologically relevant concentrations
Critical caveat: animal model safety does not reliably predict human safety for any compound
Abbreviation overlap with indole-3-propionic acid (IPA) creates identification risk; these are distinct compounds with distinct data sets
Not manufactured to pharmaceutical GMP standards when sourced from research chemical suppliers
Long-term effects entirely unknown; no chronic exposure data in any species

Drug & supplement interactions

N
o
h
u
m
a
n
p
h
a
r
m
a
c
o
k
i
n
e
t
i
c
o
r
d
r
u
g
-
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
e
x
i
s
t
f
o
r
I
P
A
M
.
T
h
e
o
r
e
t
i
c
a
l
c
o
n
s
i
d
e
r
a
t
i
o
n
s
b
a
s
e
d
o
n
i
t
s
i
n
d
o
l
e
s
t
r
u
c
t
u
r
e
a
n
d
m
i
t
o
c
h
o
n
d
r
i
a
l
t
a
r
g
e
t
i
n
c
l
u
d
e
p
o
s
s
i
b
l
e
a
d
d
i
t
i
v
e
o
r
s
y
n
e
r
g
i
s
t
i
c
e
f
f
e
c
t
s
w
i
t
h
o
t
h
e
r
m
i
t
o
c
h
o
n
d
r
i
a
-
a
c
t
i
v
e
c
o
m
p
o
u
n
d
s
(
e
.
g
.
,
C
o
Q
1
0
,
M
i
t
o
Q
,
i
d
e
b
e
n
o
n
e
)
o
r
w
i
t
h
a
g
e
n
t
s
t
h
a
t
a
f
f
e
c
t
C
o
m
p
l
e
x
I
a
c
t
i
v
i
t
y
,
b
u
t
t
h
i
s
i
s
s
p
e
c
u
l
a
t
i
v
e
a
n
d
u
n
s
t
u
d
i
e
d
.
N
o
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
i
n
a
n
y
h
u
m
a
n
p
o
p
u
l
a
t
i
o
n
.

Who should avoid it

Use in humans outside of a supervised clinical trial context
Conflating IPAM with indole-3-propionic acid (IPA) - these are distinct compounds; IPA has some human data, IPAM does not
Sourcing from suppliers who do not provide independent purity certification
Extrapolating rotifer or Drosophila lifespan data to human longevity outcomes
Use by pregnant or breastfeeding individuals (no safety data)
Use alongside mitochondria-targeting drugs or supplements without medical supervision

How it is commonly combined

No human stacking data exist. In preclinical research, IPAM has been studied in isolation. Its proposed mechanism of reducing electron leakage at Complex I suggests it could theoretically complement other mitochondrial support strategies, but no combination studies in humans or animals have been published. Any combination use is entirely unstudied and cannot be recommended outside a controlled research setting.

Legal & regulatory. Not FDA-approved as a drug or dietary supplement. Holds an FDA UNII identifier (6RD94WRM73) but no regulatory review has been completed. Sold commercially by chemical suppliers (EON Biotech, Chem-Impex, Crescent Chemical) as a research compound only. Not legal for human consumption in the United States. Patent applications (US20070105937A1; WO2005062851A2) were filed with NIH support but the US application was abandoned and never issued; patent protection has lapsed.

Quality & harm reduction

I
P
A
M
i
s
a
v
a
i
l
a
b
l
e
f
r
o
m
r
e
s
e
a
r
c
h
c
h
e
m
i
c
a
l
s
u
p
p
l
i
e
r
s
(
E
O
N
B
i
o
t
e
c
h
,
C
h
e
m
-
I
m
p
e
x
,
C
r
e
s
c
e
n
t
C
h
e
m
i
c
a
l
)
a
s
a
b
u
l
k
r
e
a
g
e
n
t
-
g
r
a
d
e
c
o
m
p
o
u
n
d
.
I
t
i
s
n
o
t
p
r
o
d
u
c
e
d
u
n
d
e
r
p
h
a
r
m
a
c
e
u
t
i
c
a
l
G
M
P
c
o
n
d
i
t
i
o
n
s
.
P
u
r
i
t
y
a
n
d
i
d
e
n
t
i
t
y
s
p
e
c
i
f
i
c
a
t
i
o
n
s
v
a
r
y
b
y
s
u
p
p
l
i
e
r
a
n
d
l
o
t
.
N
o
p
h
a
r
m
a
c
e
u
t
i
c
a
l
-
g
r
a
d
e
f
o
r
m
u
l
a
t
i
o
n
e
x
i
s
t
s
.
T
h
e
a
b
a
n
d
o
n
e
d
p
a
t
e
n
t
m
e
a
n
s
t
h
e
r
e
i
s
n
o
p
r
o
p
r
i
e
t
a
r
y
m
a
n
u
f
a
c
t
u
r
i
n
g
s
t
a
n
d
a
r
d
e
n
f
o
r
c
e
d
.
B
u
y
e
r
s
s
h
o
u
l
d
r
e
q
u
e
s
t
c
e
r
t
i
f
i
c
a
t
e
s
o
f
a
n
a
l
y
s
i
s
w
i
t
h
t
h
i
r
d
-
p
a
r
t
y
H
P
L
C
a
n
d
N
M
R
c
o
n
f
i
r
m
a
t
i
o
n
;
l
o
t
-
t
o
-
l
o
t
c
o
n
s
i
s
t
e
n
c
y
i
s
n
o
t
g
u
a
r
a
n
t
e
e
d
i
n
t
h
e
r
e
s
e
a
r
c
h
c
h
e
m
i
c
a
l
m
a
r
k
e
t
.

Safer, legal alternative we recommend

NMN It To Win It. For the same cellular-aging/longevity goal, our NMN (a NAD+ precursor) is a legal supplement covering a similar mechanism.

See our recommended pick

Find Indolepropionamide (IPAM) →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

What dose of IPAM should I take?

No safe or effective human dose has been established. IPAM has not been studied in human clinical trials. The concentrations used in preclinical models cannot be reliably converted to a human dose. Consult a licensed clinician before using any investigational research compound.

Is IPAM the same as indole-3-propionic acid (IPA)?

No. These are two different compounds that share a confusing abbreviation overlap. Indole-3-propionic acid (IPA) is a gut microbiome metabolite with some limited human data. Indolepropionamide (IPAM) is a distinct molecule - an amide, not an acid - with no human trial data. Do not conflate the two or assume IPA safety data applies to IPAM.

Has IPAM been tested in humans?

No. As of the available literature, no published human clinical trials have been conducted specifically for indolepropionamide (IPAM). All published evidence is from animal models (rotifers, mice, rats, Drosophila) and in vitro cell culture experiments.

Why was the IPAM patent abandoned?

The specific reasons for abandonment of the US patent application (US20070105937A1, filed December 2004) are not publicly documented in the research notes. Patent abandonment can reflect many factors - cost, strategic decisions, failure to prosecute, or a decision not to pursue commercial development - and does not necessarily indicate a safety finding or negative efficacy result.

Is IPAM legal to purchase?

In the United States, IPAM is available from research chemical suppliers as an investigational compound for laboratory use. It is not FDA-approved as a drug or dietary supplement and is not legal for human consumption. Regulatory status varies by country and should be verified locally before purchase.

What is the most significant evidence for IPAM?

The most-cited preclinical finding is a 2010 PLOS ONE study (PMID 20421998) reporting approximately 300% lifespan extension in the rotifer Philodina roseola. While striking in a model organism context, rotifer lifespan data does not translate directly to mammals or humans. Rodent mitochondrial studies show protection at nanomolar concentrations, but no human trials have followed from this work.

References & further reading

PubMed: PMID 20421998 - A Novel Endogenous Indole Protects Rodent Mitochondria and Extends Rotifer Lifespan (PLOS ONE 2010)
PubMed: search terms - indolepropionamide mitochondria aged rodent Complex I
PubMed: PMC12762571 - IPA improves muscle function and reduces bone loss in aged mice and modulates lifespan in Drosophila melanogaster
Google Patents: US20070105937A1 - Indole-3-propionamide and derivatives therapeutic formulations
ClinicalTrials.gov: search terms - indole propionic acid Friedreich ataxia (note: IPA trials, not IPAM; cited for structural analogue tolerability context only)